Intrinsa (testosterone)
- Region
- 🇪🇺 EU
- Active substance
- testosterone
- Company
- Warner Chilcott UK Ltd.
- Status
- Withdrawn
- Therapeutic area
- Sexual Dysfunctions, Psychological
- EU approval
- Fri 28 Jul 2006
- Application
- EMEA/H/C/000634
- ATC
- G03BA03
- Official record
- www.ema.europa.eu
Indication
Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Livensa Withdrawn · Warner Chilcott Deutschland GmbH
Follow Intrinsa
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.